Strategic Partnerships Ashvattha has recently appointed executives with corporate development and strategic partnership focus, signaling a readiness to engage in collaborations that can accelerate clinical programs and co-development opportunities. Target potential partners in ophthalmology, neurology, and oncology, emphasizing access to the HD platform for joint development or licensing.

Clinical Momentum Positive Phase II results for migaldendranib in DME and nAMD with ongoing pivotal program alignment suggest continued clinical upside. Sales outreach should prioritize eye care networks, specialty clinics, and payer discussions around differentiated subcutaneous and systemic delivery of HDT-based therapies.

Therapeutic Scope A broad addressable market spanning neurology, ophthalmology, hyperinflammatory diseases, and neuro-oncology indicates cross-domain collaboration opportunities. Propose cross-portfolio strategies with CROs, biotech co-developers, and pharma in multi-indication pipelines leveraging the HD delivery platform.

Market Presence Active participation in key retina and radiology/oncology congresses (EURETINA, ARVO, SNMMI, MaculArt) demonstrates visibility to specialists. Leverage conference relationships to set up pilot studies, speaking engagements, and targeted joint symposiums with potential customers and investors.

Funding and Growth Significant funding runway combined with a lean team (11-50 employees) creates an opportunity to pursue licensing deals, strategic partnerships, and contract manufacturing collaborations. Highlight opportunities for CDMO, manufacturing scale-up, and supply chain partnerships to support expanding trials and eventual commercialization.